Fortress Biotech (FBIO) Surpasses Q3 Earnings Estimates

Core Insights - Fortress Biotech reported quarterly earnings of $0.11 per share, significantly beating the Zacks Consensus Estimate of a loss of $0.43 per share, marking an earnings surprise of +125.58% [1] - The company posted revenues of $17.63 million for the quarter ended September 2025, which was 25.55% below the Zacks Consensus Estimate, but an increase from $14.63 million year-over-year [2] - Fortress Biotech shares have increased approximately 23% since the beginning of the year, outperforming the S&P 500's gain of 14.6% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.49 on revenues of $27.49 million, while for the current fiscal year, the estimate is -$1.18 on revenues of $80.7 million [7] - The estimate revisions trend for Fortress Biotech was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Fortress Biotech belongs, is currently ranked in the top 36% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]